Section 200: Epigenetic and Chromatin Therapy in CBS/PSP

therapeutic

Section 200: Epigenetic and Chromatin Therapy in CBS/PSP

Overview

<table class=“infobox infobox-therapeutic”> <tr> <th class=“infobox-header” colspan=“2”>Section 200: Epigenetic and Chromatin Therapy in CBS/PSP</th> </tr> <tr> <td class=“label”>Modification</td> <td>Change</td> </tr> <tr> <td class=“label”>H3K9ac (acetylation)</td> <td>Decreased at synaptic genes</td> </tr> <tr> <td class=“label”>H3K27me3 (trimethylation)</td> <td>Increased globally</td> </tr> <tr> <td class=“label”>H4K16ac</td> <td>Reduced in neurons</td> </tr> <tr> <td class=“label”>H3K4me3</td> <td>Altered at tau regulators</td> </tr> <tr> <td class=“label”>Parameter</td> <td>Value</td> </tr> <tr> <td class=“label”>Primary Target</td> <td>HDAC1, HDAC2, HDAC3</td> </tr> <tr> <td class=“label”>BBB Penetration</td> <td>Moderate</td> </tr> <tr> <td class=“label”>Common Dose</td> <td>500-1500 mg/day</td> </tr> <tr> <td class=“label”>Key Side Effects</td> <td>Weight gain, tremor, hepatotoxicity</td> </tr> <tr> <td class=“label”>Parameter</td> <td>Value</td> </tr> <tr> <td class=“label”>Primary Target</td> <td>HDAC1, HDAC3</td> </tr> <tr> <td class=“label”>Stage</td> <td>Phase 1/2 in oncology</td> </tr> <tr> <td class=“label”>BBB Penetration</td> <td>Under investigation</td> </tr> <tr> <td class=“label”>Key Advantage</td> <td>Isoform selectivity</td> </tr> <tr> <td class=“label”>Parameter</td> <td>Value</td> </tr> <tr> <td class=“label”>Primary Target</td> <td>HDAC6</td> </tr> <tr> <td class=“label”>Selectivity</td> <td>>100-fold vs Class I</td> </tr> <tr> <td class=“label”>Preclinical Status</td> <td>Active development</td> </tr> <tr> <td class=“label”>Key Benefit</td> <td>Cytoplasmic mechanism</td> </tr> <tr> <td class=“label”>Agent</td> <td>Target</td> </tr> <tr> <td class=“label”>Resveratrol</td> <td>SIRT1</td> </tr> <tr> <td class=“label”>SRT2104</td> <td>SIRT1</td> </tr> <tr> <td class=“label”>SRT3025</td> <td>SIRT1</td> </tr> <tr> <td class=“label”>Agent</td> <td>Indication</td> </tr> <tr> <td class=“label”>5-azacytidine</td> <td>Myelodysplastic syndrome</td> </tr> <tr> <td class=“label”>Decitabine</td> <td>MDS</td> </tr> <tr> <td class=“label”>Agent</td> <td>Company</td> </tr> <tr> <td class=“label”>Pelabresib (CPI-0610)</td> <td>Constellation</td> </tr> <tr> <td class=“label”>ABBV-744</td> <td>AbbVie</td> </tr> <tr> <td class=“label”>OTX015</td> <td>OncoEthix</td> </tr> <tr> <td class=“label”>Phase</td> <td>Agent</td> </tr> <tr> <td class=“label”>1</td> <td>Entinostat</td> </tr> <tr> <td class=“label”>2</td> <td>Break</td> </tr> <tr> <td class=“label”>3</td> <td>BET inhibitor</td> </tr> <tr> <td class=“label”>4</td> <td>Assessment</td> </tr> <tr> <td class=“label”>Epigenetic Agent</td> <td>Interaction</td> </tr> <tr> <td class=“label”>Valproic acid</td> <td>Additive CNS effects</td> </tr> <tr> <td class=“label”>DNMT inhibitors</td> <td>None</td> </tr> <tr> <td class=“label”>BET inhibitors</td> <td>None</td> </tr> <tr> <td class=“label”>HDAC6 inhibitors</td> <td>None</td> </tr> <tr> <td class=“label”>Therapy</td> <td>Monitoring Parameters</td> </tr> <tr> <td class=“label”>Valproic acid</td> <td>Liver function, ammonia</td> </tr> <tr> <td class=“label”>DNMT inhibitors</td> <td>Blood counts</td> </tr> <tr> <td class=“label”>BET inhibitors</td> <td>Platelets, GI symptoms</td> </tr> <tr> <td class=“label”>HDAC6 inhibitors</td> <td>Motor function</td> </tr> <tr> <td class=“label”>Category</td> <td>Score</td> </tr> <tr> <td class=“label”>Scientific Rationale</td> <td>8/10</td> </tr> <tr> <td class=“label”>Preclinical Evidence</td> <td>6/10</td> </tr> <tr> <td class=“label”>Clinical Evidence</td> <td>2/10</td> </tr> <tr> <td class=“label”>Safety Profile</td> <td>5/10</td> </tr> <tr> <td class=“label”>CNS Penetration</td> <td>3/10</td> </tr> <tr> <td class=“label”>Patient Accessibility</td> <td>2/10</td> </tr> <tr> <td class=“label”>Total</td> <td>26/50</td> </tr> </table>

Epigenetic dysregulation represents a fundamental pathological feature in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). These tauopathies exhibit widespread disturbances in chromatin architecture, DNA methylation patterns, and histone modifications that contribute to transcriptional dysfunction, tau pathology propagation, and neuronal death 1.

This section provides comprehensive coverage of epigenetic and chromatin-based therapeutic strategies, building upon foundational concepts in Section 41 (basic epigenetic modifications) and Section 192 (advanced epigenomics). Here we focus on specific therapeutic implementation, clinical evidence, and integration with existing treatment regimens.

The therapeutic rationale targets the root cause of transcriptional dysregulation that characterizes these disorders. Unlike symptomatic treatments, epigenetic therapies aim to restore proper gene expression patterns and potentially slow or modify disease progression.

Molecular Basis of Epigenetic Dysregulation in CBS/PSP

Histone Modifications in Tauopathy

Histone proteins undergo post-translational modifications that regulate chromatin accessibility. In CBS and PSP, several key alterations have been documented:

Histone deacetylases (HDACs) are a family of enzymes that remove acetyl groups from histone tails, generally promoting transcriptional repression. In tauopathies, HDAC activity is frequently dysregulated, leading to abnormal gene silencing 2.

DNA Methylation Patterns

DNA methylation involves the addition of methyl groups to cytosine residues, typically at CpG dinucleotides. Research demonstrates:

  • Global hypomethylation in tauopathy brains, particularly at repetitive elements 3
  • Gene-specific hypermethylation at promoters of neuroprotective genes
  • Epigenetic age acceleration correlating with disease severity

Chromatin Architecture Defects

Beyond individual modifications, the three-dimensional organization of chromatin is disrupted in CBS/PSP:

  • Heterochromatin decondensation leading to genomic instability
  • Topologically associated domain (TAD) disruption altering enhancer-promoter interactions
  • Nuclear lamina abnormalities affecting peripheral heterochromatin

Histone Deacetylase (HDAC) Inhibitors

Class I HDAC Inhibitors (HDAC1, 2, 3)

Class I HDACs are primarily nuclear localized and regulate gene expression through histone deacetylation. Their inhibition can restore synaptic plasticity and memory formation 4.

Valproic Acid

Mechanism: Broad-spectrum HDAC inhibitor, primarily targeting Class I HDACs. Increases histone acetylation at promoters of synaptic genes.

Clinical Evidence: A clinical trial in PSP showed mixed results 5. While generally well-tolerated, valproic acid has limited CNS penetration and significant side effect burden.

NET Assessment: 18/50 (36%) — Limited by side effects and moderate efficacy

Entinostat (MS-275)

Mechanism: Class I-selective HDAC inhibitor with enhanced potency compared to valproic acid. Specifically targets HDAC1 and HDAC3.

Preclinical Evidence: Promising results in tauopathy models showing:

  • Reduced tau phosphorylation
  • Enhanced autophagy of tau aggregates
  • Improved synaptic markers

NET Assessment: 24/50 (48%) — More selective but clinical data limited

HDAC6 Inhibitors

HDAC6 is primarily cytoplasmic and regulates microtubule function, tau acetylation, and aggresome clearance. Unlike Class I HDACs, HDAC6 inhibition does not directly affect gene transcription.

Tubastatin A

Mechanism: Highly selective HDAC6 inhibitor that increases alpha-tubulin acetylation and promotes tau clearance through enhanced aggrephagy.

ACY-121 (Ricolinostat)

Mechanism: HDAC6 inhibitor in clinical trials for oncology. Promotes tau acetylation and clearance.

Clinical Status: Phase 1/2 trials completed in multiple myeloma. Neurodegeneration applications in development.

NET Assessment: 26/50 (52%) — Promising mechanism, HDAC6 selectivity reduces transcriptional effects

Sirtuin Modulators (SIRT1, SIRT2)

Sirtuins are NAD±dependent deacetylases with distinct cellular functions:

  • SIRT1: Nuclear, promotes longevity gene expression
  • SIRT2: Cytoplasmic, regulates microtubule dynamics

SIRT1 Activators

Resveratrol: Natural SIRT1 activator with some evidence for neuroprotection in tauopathy models.

NET Assessment: 16/50 (32%) — Weak evidence for specific tauopathy benefit

SIRT2 Inhibitors

AGK2: SIRT2-selective inhibitor showing promise in Parkinson’s disease models. May benefit CBS/PSP through microtubule stabilization.

NET Assessment: 18/50 (36%) — Early stage, novel mechanism

DNA Methyltransferase (DNMT) Inhibitors

Overview

DNA methyltransferase inhibitors can reverse aberrant DNA methylation patterns that silence neuroprotective genes. Two FDA-approved agents have been studied in neurodegeneration:

Challenges and Limitations

  1. Blood-brain barrier penetration: Both agents have poor CNS delivery
  2. Myelosuppression: Hematologic toxicity limits chronic dosing
  3. Non-selective effects: Global hypomethylation may cause genomic instability
  4. Delayed onset: Epigenetic changes require weeks to months

Clinical Considerations

DNMT inhibitors have shown promise in preclinical tauopathy models 6 but face significant translation barriers:

  • Compassionate use: Possible through oncology consultation
  • Novel analogs: CNS-selective agents in development
  • Combination potential: May synergize with HDAC inhibitors

NET Assessment: 14/50 (28%) — Strong mechanistic rationale but significant delivery challenges

Bromodomain and Extra-Terminal Domain (BET) Inhibitors

Mechanism

BET proteins (BRD2, BRD3, BRD4, BRDT) bind acetylated histone tails and regulate transcriptional elongation. Their inhibition offers several therapeutic advantages in tauopathy:

  • Reduced tau expression: BRD4 regulates tau gene transcription
  • Anti-inflammatory effects: Downregulation of cytokine expression
  • Enhanced autophagy: Transcriptional activation of autophagy genes

Clinical-Stage Agents

Evidence in Tauopathy

Preclinical studies demonstrate BET inhibition reduces tau pathology and improves cognitive function 7:

  • Tau expression: Reduced at transcriptional level
  • Tau aggregation: Decreased in cellular models
  • Cognition: Improved in mouse models

NET Assessment: 28/50 (56%) — Strongest evidence among epigenetic approaches

Chromatin Remodeling Complexes

SWI/SNF Complex

The SWI/SNF (SWitch/Sucrose Non-Fermentable) complex uses ATP to slide nucleosomes and regulate chromatin accessibility. Components frequently mutated in tauopathies include:

  • ARID1A/BAF250: Reduced expression correlates with tau burden
  • SMARCA4/BRG1: Decreased in PSP brains
  • SMARCA2: Therapeutic target for restoration

Therapeutic Strategies

  1. HDAC3 inhibition: HDAC3 is part of the SWI/SNF complex; its inhibition enhances function
  2. BAF250 agonists: In discovery phase
  3. Gene therapy: Viral delivery of SMARCA4

NET Assessment: 16/50 (32%) — Early stage but addresses root cause

Polycomb Complexes

The Polycomb Repressive Complex 2 (PRC2), particularly EZH2, is overactive in tauopathies:

  • EZH2 inhibitors: Tazemetostat (FDA-approved for sarcoma) may have applications
  • H3K27me3 reduction: Restores expression of silenced neuroprotective genes

Combined Epigenetic Therapy

Rationale for Combination

Epigenetic modifications interact extensively; combined approaches may achieve greater efficacy:

  1. HDAC + DNMT inhibitors: Synergistic demethylation
  2. HDAC + BET inhibitors: Combined transcriptional activation
  3. Multiple HDAC isoforms: Broader target coverage

Protocol Example

Caution: Combination therapy increases toxicity risk and requires careful monitoring.

Integration with Current Treatment Regimen

Levodopa/Carbidopa

Epigenetic therapies have minimal direct interactions:

  • No effect on dopamine metabolism
  • Standard monitoring sufficient
  • Potential for additive CNS effects

Rasagiline (MAO-B Inhibitor)

Adverse Event Monitoring

NET Assessment Summary

Patient Recommendations

Immediate Actions (1-2 weeks)

  1. Monitor for clinical trials: BET inhibitors and HDAC6 inhibitors in upcoming trials
  2. Consult neurology: Discussion of valproic acid off-label use
  3. Dietary considerations: Sulforaphane-rich foods for natural HDAC modulation

Short-Term (1-3 months)

  1. Epigenetic age testing: Establish baseline (Horvath/GrimAge)
  2. Genetic counseling: Assess DNMT variants
  3. Seek academic center: Access to experimental protocols

Long-Term (3-12 months)

  1. Trial enrollment priority: Especially for BET and HDAC6 inhibitors
  2. Biomarker tracking: Monitor epigenetic age and methylation patterns
  3. Combination therapy: Pending emerging evidence

Cross-Links

References

  1. Bardai FH, et al. Histone deacetylase dysfunction in tauopathies (2018)
  2. Rouaux C, et al. Class I HDAC manipulation for neurodegenerative diseases (2017)
  3. Grayson DR, et al. Epigenetic alterations in tauopathy brains (2020)
  4. Min SW, et al. Critical role of HDAC2 in synaptic plasticity (2010)
  5. Adam R, et al. Valproic acid treatment in PSP (2013)
  6. Chen X, et al. DNA hypomethylation in tauopathies (2019)
  7. Kelley MW, et al. BET bromodomain inhibition in tauopathies (2019)